Patent: 10,350,178
✉ Email this page to a colleague
Summary for Patent: 10,350,178
Title: | Methods and compositions for treatment of demyelinating diseases |
Abstract: | Disclosed herein is a method of prevention of progression of a multiple sclerosis in a patient, comprising the administration of methylglyoxal bis(guanylhydrazone) (MGBG) to the patient in need thereof. Also disclosed herein is a method of prevention or reduction in severity of the initiation phase of autoimmune response in a patient having multiple sclerosis, comprising the administration of MGBG to the patient in need thereof. |
Inventor(s): | Blitzer; Jeremy (San Francisco, CA), McKearn; John (St. Louis, MO) |
Assignee: | Pathologica LLC (San Francisco, CA) |
Application Number: | 16/109,824 |
Patent Claims: | see list of patent claims |
Details for Patent 10,350,178
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bayer Healthcare Pharmaceuticals Inc. | BETASERON | interferon beta-1b | For Injection | 103471 | 07/23/1993 | ⤷ Try a Trial | 2033-01-08 |
Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | 05/17/1996 | ⤷ Try a Trial | 2033-01-08 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 05/28/2003 | ⤷ Try a Trial | 2033-01-08 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 02/27/2012 | ⤷ Try a Trial | 2033-01-08 |
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2033-01-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |